Search Results - "Maiese, Eric M"

Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma by Fonseca, Rafael, Usmani, Saad Z, Mehra, Maneesha, Slavcev, Mary, He, Jianming, Cote, Sarah, Lam, Annette, Ukropec, Jon, Maiese, Eric M, Nair, Sandhya, Potluri, Ravi, Voorhees, Peter M

“…For patients with multiple myeloma (MM), each additional line of therapy (LOT) is associated with lower response rates, shorter treatment duration and…”
Get full text

Real-world treatment patterns and outcomes of triple-class treated patients with multiple myeloma in the United States by Varughese, Prateesh, Smith, Robert, Xue, Mei, Dorrow, Natalie, Hogea, Cosmina, Maiese, Eric M, Buckingham, Trudy

“…Although multiple myeloma (MM) survival has improved following the introduction of proteosome inhibitors, immunomodulatory drugs, and anti-CD38 therapies,…”
Get more information

The impact of specific HIV treatment-related adverse events on adherence to antiretroviral therapy: A systematic review and meta-analysis by Al-Dakkak, Imad, Patel, Seema, McCann, Eilish, Gadkari, Abhijit, Prajapati, Girish, Maiese, Eric M.

“…Poor adherence to antiretroviral therapies (ARTs) in human immunodeficiency virus (HIV)-infected patients increases the risk of incomplete viral suppression,…”
Get full text

Economic Burden of HIV Antiretroviral Therapy Adverse Events in the United States by Dekoven, Mitch, Makin, Charles, Slaff, Samantha, Marcus, Michael, Maiese, Eric M.

“…Objective: To estimate health care costs associated with medical events identified as antiretroviral therapy (ART)-attributable adverse events (AEs). Methods:…”
Get full text

Systematic literature review of immunoglobulin trends for anti-CD20 monoclonal antibodies in multiple sclerosis by Saidha, Shiv, Bell, Judith, Harold, Sydney, Belisario, Jose Marcano, Hawe, Emma, Shao, Qiujun, Wyse, Kerri, Maiese, Eric M.

“…Objective To exp lore changes in immunoglobulin (Ig) levels for people with relapsing-multiple sclerosis (RMS) treated with ocrelizumab or ofatumumab and the…”
Get full text

Incidence, risk factors, and consequences of residual neuromuscular block in the United States: The prospective, observational, multicenter RECITE-US study by Saager, Leif, Maiese, Eric M., Bash, Lori D., Meyer, Tricia A., Minkowitz, Harold, Groudine, Scott, Philip, Beverly K., Tanaka, Pedro, Gan, Tong Joo, Rodriguez-Blanco, Yiliam, Soto, Roy, Heisel, Olaf

“…To determine the incidence burden and associated risk factors of residual neuromuscular block (rNMB) during routine U.S. hospital care. Blinded multicenter…”
Get full text

Daratumumab Split First Versus Single Dosing Schedule Among Patients With Multiple Myeloma Treated in a US Community Oncology Setting: A Retrospective Observational Study by Rifkin, Robert, Singer, David, Aguilar, Kathleen M., Baidoo, Bismark, Maiese, Eric M.

“…Daratumumab was initially approved by the US Food and Drug Administration to be given intravenously over the course of several hours during each…”
Get full text

Real-world utilization and outcomes of systemic therapy among patients with advanced or recurrent endometrial cancer in the United States by Liu, Jinan, Emond, Bruno, Maiese, Eric M., Lafeuille, Marie-Hélène, Lefebvre, Patrick, Ghelerter, Isabelle, Wu, Caterina, Hurteau, Jean A., Thaker, Premal H.

“…Evaluate systemic therapy utilization patterns and outcomes by line of therapy among patients with advanced/recurrent endometrial cancer (EC) treated in the…”
Get full text

An Epidemiology Model for Estimating the Numbers of US Patients With Multiple Myeloma by Line of Therapy and Treatment Exposure by Nikolaou, Andreas, Hogea, Cosmina, Samyshkin, Yevgeniy, Maiese, Eric M., Sansbury, Leah, Oguz, Mustafa, Cid-Ruzafa, Javier, Kapoor, Ritika, Wang, Feng

“…Estimates on the distribution of patients with multiple myeloma (MM) by line of therapy (LOT) are scarce and get outdated quickly as new treatments become…”
Get full text

A U.S. Cost Analysis of Triplet Regimens for Patients with Previously Treated Multiple Myeloma by Hollmann, Sarah, Moldaver, Daniel, Goyert, Nik, Grima, Daniel, Maiese, Eric M

“…In recent years, the FDA has approved several 3-agent (i.e., triplet) combinations for previously treated multiple myeloma (MM), and the National Comprehensive…”
Get full text

Physician treatment preferences for relapsed/refractory multiple myeloma: a discrete choice experiment by Batchelder, Laurie, Philpott, Stephanie, Divino, Victoria, Boytsov, Natalie, Maiese, Eric M, Hogea, Cosmina, Buckingham, Trudy, Chen, Chi-Chang, Rodriguez, Ana Maria

“…This study aimed to assess physician preferences for later lines (third to fifth) of therapy in patients with relapsed/refractory multiple myeloma (RRMM) in…”
Get full text

Daratumumab‐lenalidomide‐dexamethasone vs standard‐of‐care regimens: Efficacy in transplant‐ineligible untreated myeloma by Durie, Brian G. M., Kumar, Shaji K., Usmani, Saad Z., Nonyane, Bareng A. S., Ammann, Eric M., Lam, Annette, Kobos, Rachel, Maiese, Eric M., Facon, Thierry

“…Daratumumab in combination with lenalidomide‐dexamethasone (D‐Rd) recently received FDA approval for the treatment of transplant‐ineligible patients with newly…”
Get full text

Real-world cost of care and site of care in patients with multiple sclerosis initiating infused disease-modifying therapies by Alvarez, Enrique, Nair, Kavita V, Tan, Hiangkiat, Rathi, Kapil, Gabler, Nicole B, Maiese, Eric M, Deshpande, Chinmay, Shao, Qiujun

“…Evaluate the real-world costs over two years and costs by site of care for ocrelizumab (OCR), natalizumab (NTZ), and alemtuzumab (ATZ) in patients with…”
Get more information

Budget impact analysis of niraparib for first-line maintenance therapy in advanced ovarian cancer from a US payer perspective by Liu, Jinan, Hawkes, Carol, Walder, Lydia, Spalding, Chloe, Travers, Karin, Maiese, Eric M, Hurteau, Jean

“…Ovarian cancer (OC) is the fifth leading cause of cancer death in women and has the highest mortality rate of gynecological cancers. Niraparib was recently…”
Get full text

Letter--The Authors Respond by Hollmann, Sarah, Moldaver, Daniel, Goyert, Nik, Grima, Daniel, Maiese, Eric M.

Get full text

Comparative Efficacy of Treatments for Previously Treated Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis by Maiese, Eric M., Ainsworth, Claire, Le Moine, Jean-Gabriel, Ahdesmäki, Outi, Bell, Judith, Hawe, Emma

“…New therapies, including daratumumab plus lenalidomide plus dexamethasone (DRd) and daratumumab plus bortezomib plus dexamethasone (DVd), have recently been…”
Get full text

Incidence of corneal adverse events in patients with multiple myeloma and their clinical and economic impact: A real-world retrospective cohort study by Wang, Feng, Sansbury, Leah, Ferrante, Shannon, Maiese, Eric M, Willson, Jenny, Chen, Chi-Chang, Nunna, Sasikiran, Sun, Kainan, Kleinman, David M

“…Ocular toxicities are common adverse events (AEs) associated with anticancer agents. There is a paucity of data documenting their impact on patient care. This…”
Get more information

In Reply: Network Meta-analyses Are Not About a Single Treatment But About Sets of Regimens by Maiese, Eric M., Ainsworth, Claire, Le Moine, Jean-Gabriel, Ahdesmӓki, Outi, Bell, Judith, Hawe, Emma

“…The NMA would then not provide a clear comparison of adverse–events profiles, when those profiles differ by treatment. [...]we agree with Panjabi and Iskander…”
Get full text

Quality of life of HIV-infected patients who switch antiretroviral medication due to side effects or other reasons by Maiese, Eric M., Johnson, Phaedra T., Bancroft, Tim, Goolsby Hunter, Alyssa, Wu, Albert W.

“…Objective: The objective of this study was to investigate changes in health-related quality of life (HRQOL) among HIV patients following switch from a first-…”
Get full text

Real-world use of ofatumumab to treat multiple sclerosis 9 months post-FDA approval during COVID-19 pandemic by Coyle, Patricia K., Gorritz, Magdaliz, Wade, Rolin L., Zhou, Zifan, Khalid, Subhan, Maiese, Eric M., Deshpande, Chinmay, Shao, Qiujun Samantha

“…•First real-world complete look at ofatumumab initiation during COVID-19 pandemic.•Baseline enrollment covered a wide age range and included patients aged ≥55…”
Get full text